Welcome to the first issue of The Peptide Signal. Each Tuesday, four sections: a landmark study broken down, a protocol examined, a mechanism explained, and the week's regulatory news, without the vendor spin. The intro is free. Full issue is for subscribers.
The biggest obesity drug data drop in years. A mitochondrial peptide gets its first FDA approval. And the most consequential regulatory shift in the peptide compounding space since 2023, with an important caveat that most coverage is missing.
Novo Nordisk's stock dropped 9% the morning of June 22, 2025. The headline from REDEFINE 1: CagriSema produced 20.4% mean body weight reduction at 68 weeks in adults with obesity. That number was below the 25% the market had been expecting, and investors sold.
The same morning, researchers published that result in the New England Journal of Medicine.
Here is what actually happened in that trial, and why the market reaction tells you more about analyst expectations than it does about the compound.
What CagriSema is
CagriSema is a fixed-dose combination of two once-weekly injectable compounds: cagrilintide 2.4 mg (a long-acting amylin analogue) and semaglutide 2.4 mg (the same active ingredient as Wegovy). The two compounds target different but complementary appetite pathways. Semaglutide works primarily through GLP-1 receptor activation in the gut and brain. Cagrilintide works through amylin and calcitonin receptors in the hindbrain and hypothalamus, areas involved in both hunger signaling and satiety. The theoretical basis for combining them is that they hit the same behavioral outcome through independent biological routes.
What REDEFINE 1 actually found
REDEFINE 1 enrolled 3,417 adults without type 2 diabetes who had obesity or overweight with at least one weight-related complication. Participants were randomized in a 21:3:3:7 ratio to CagriSema, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo. All groups received lifestyle intervention. The trial ran 68 weeks.
The results by arm: CagriSema 20.4% mean weight loss (treatment-policy estimand), semaglutide alone 14.9%, cagrilintide alone 11.5%, placebo 3.0%. The combination outperformed either component alone. The difference between CagriSema and semaglutide monotherapy was 5.5 percentage points. 60% of CagriSema participants achieved at least 20% body weight reduction. 23% achieved at least 30%. On the trial-product estimand, the number rises to 22.7%. The combination also improved systolic blood pressure, waist circumference, lipid levels, and glycemic control. In participants with prediabetes, 88% returned to normoglycemia.
The bottom line
CagriSema works. The combination adds meaningful weight loss beyond what either component achieves alone. The 20.4% figure is better than every approved drug on the market, framed against the actual clinical comparison set rather than analyst models. The high GI adverse event rate is the real limitation to watch as more safety data emerges. The market got this one wrong. The biology is intact.
Full premium section: mechanism of dual-pathway satiety suppression, cagrilintide DACRA profile versus pramlintide, REDEFINE 2 diabetes population results (13.7% weight loss), 88% normoglycemia reversal context, and competitive positioning through 2027.
The disappointment in context
The 25% figure that analysts were expecting came from Phase 2 data and early modeling. Phase 2 trials consistently overestimate effect sizes, and this is not specific to CagriSema. The trial used a treatment-policy estimand, which includes participants who discontinued or used rescue therapy, and intentionally produces more conservative figures than the idealized trial-product estimand. This is the methodologically appropriate way to report results for regulatory purposes. It is also consistently lower than what Phase 2 trials report.
20.4% is higher than any approved weight loss drug has achieved in a comparably designed trial. Semaglutide's STEP program, across five major trials, produced 15 to 17% weight loss. Tirzepatide achieved 20 to 21% in the SURMOUNT program. CagriSema at 20.4% lands above semaglutide and approximately level with tirzepatide, and this is the combination's Phase 3 result in a non-diabetic obesity population. The market sold because the number was below an arbitrary expectation. The science shows a drug that outperforms all currently approved alternatives.
What was less good
Gastrointestinal adverse events affected 79.6% of CagriSema participants versus 39.9% in the placebo group. Most were described as transient and mild to moderate. Nausea, vomiting, diarrhea, and constipation followed the pattern typical of GLP-1 therapies but at higher rates than semaglutide monotherapy. This is the expected tradeoff for additional pharmacological activity. Discontinuation data was not separately reported in the topline data available at time of writing. Detailed results are expected at a future medical meeting and in the peer-reviewed publication.
Regulatory status
Novo Nordisk filed a New Drug Application with the FDA in December 2025. FDA review is expected in 2026, with potential approval as early as late 2026 or early 2027. CagriSema is not approved anywhere as of this writing.
The dual-pathway satiety mechanism
The complementary mechanism of CagriSema explains why the combination outperforms either component alone rather than simply adding their effects. GLP-1 receptor agonists like semaglutide act primarily on the vagus nerve and brainstem to reduce gastric emptying and on the arcuate nucleus of the hypothalamus to suppress appetite. The effect is primarily on caloric intake through delayed gastric emptying and centrally mediated satiety signals.
Amylin analogues like cagrilintide act through a different set of receptors: heterodimers of the calcitonin receptor combined with receptor activity modifying proteins (RAMP1, RAMP2, RAMP3) in the area postrema and nucleus of the solitary tract, regions in the hindbrain with incomplete blood-brain barrier coverage. These are distinct from the primary GLP-1 receptor sites. The amylin system particularly affects the hedonic drive to eat (wanting food for reward rather than hunger), which the GLP-1 system addresses less directly. The combination suppresses both homeostatic hunger and hedonic appetite through independent neural pathways.
REDEFINE 2: the diabetes population
The concurrent REDEFINE 2 trial enrolled 1,206 adults with type 2 diabetes and obesity or overweight. CagriSema produced 13.7% mean weight loss at 68 weeks versus 3.4% with placebo, a difference of 10.4 percentage points. 73.5% of CagriSema participants achieved a glycated hemoglobin level of 6.5% or below, compared with 15.9% in the placebo group.
The 13.7% figure in REDEFINE 2 is lower than the 20.4% in REDEFINE 1. This pattern (lower weight loss in diabetic populations) has been consistently observed across GLP-1 therapies and reflects physiological differences in how type 2 diabetes modifies the incretin response. The regulatory significance is that CagriSema demonstrated efficacy in both populations, which will likely support label indications for both obesity and type 2 diabetes.
What 88% normoglycemia reversal means
In REDEFINE 1, 88% of participants with prediabetes returned to normoglycemia at 68 weeks. Prediabetes affects approximately 96 million adults in the United States, roughly 38% of the adult population. Weight loss is the most effective intervention for prediabetes reversal, but sustained weight loss is difficult to achieve without pharmacological support. A drug producing 20.4% weight loss with 88% prediabetes reversal at 68 weeks represents a meaningful clinical intervention for a condition that progresses to type 2 diabetes at a rate of approximately 5 to 10% annually without intervention. Whether this normoglycemia is durable after treatment cessation is the key outstanding question, consistent with data from semaglutide showing weight regain after discontinuation.
Competitive positioning through 2027
The obesity drug competitive landscape through 2027 will be defined by three compounds: semaglutide (approved, dominant market share), tirzepatide (approved, rapidly gaining), and the next-generation candidates. CagriSema (FDA decision expected late 2026 or early 2027) and retatrutide (approval not expected before late 2027) are the two most advanced next-generation candidates. CagriSema at 20.4% positions it above semaglutide but approximately level with tirzepatide's SURMOUNT results. Retatrutide's TRIUMPH-4 result of 28.7% in the osteoarthritis population, if replicated in the pure obesity TRIUMPH-1 and TRIUMPH-2 trials, would place it clearly above all approved competitors. The market is large enough for multiple winners.
The headline from Eli Lilly's TRIUMPH-4 Phase 3 trial, announced in December 2025, was 28.7% body weight reduction at 68 weeks. That number is real and it is remarkable. But TRIUMPH-4 was not a pure obesity trial.
TRIUMPH-4 enrolled 445 adults who had both obesity or overweight and knee osteoarthritis. The trial's co-primary endpoints were percent change in body weight and change in WOMAC pain subscale score. Lilly was testing whether a triple agonist could simultaneously produce substantial weight loss and clinically meaningful pain reduction in a population defined by a specific obesity complication.
Both endpoints were met. Retatrutide 12 mg produced 28.7% weight loss and reduced WOMAC pain scores by 4.5 points, a 75.8% reduction from a baseline score of 6.0. More than 1 in 8 participants on retatrutide 12 mg reported complete freedom from knee pain at week 68. Cardiovascular risk markers improved across the board: non-HDL cholesterol, triglycerides, high-sensitivity CRP, and systolic blood pressure (down 14.0 mmHg at 12 mg).
What this data does and does not tell you
28.7% is the largest weight loss figure ever recorded in a Phase 3 trial. But this is the osteoarthritis population, not the general obesity population. The TRIUMPH-1 and TRIUMPH-2 trials, which are studying retatrutide in general obesity and will form the basis of FDA approval for that indication, have not yet reported. Their results are expected in 2026. The distinction matters because patients with obesity and established knee osteoarthritis may have specific characteristics, including distribution of adiposity, inflammatory burden, and baseline metabolic status, that could influence response magnitude. Whether 28.7% will replicate in the broader obesity population is the critical outstanding question.
The new safety signal
TRIUMPH-4 identified dysesthesia (tingling, numbness, or abnormal skin sensations) in up to 21% of participants at the 12 mg dose. This was not observed in Phase 2 trials for retatrutide. It did not appear to drive discontinuation at meaningful rates, and Lilly characterized the events as generally mild. But this is a novel finding that will be watched closely in the remaining seven TRIUMPH readouts expected through 2026. Discontinuation rates were 18.2% at 12 mg versus 4.0% in placebo. Some discontinuations were attributed to perceived excessive weight loss: lower baseline BMI participants may have hit their weight floor faster than participants in a pure obesity trial.
Protocol context and dose escalation
Retatrutide is investigational and not FDA-approved. The compound is not available through licensed prescribers. Research-grade material is available through the gray market, but the FDA's enforcement posture toward Category 2 and related compounds remains unsettled. Any protocol discussion is strictly in the context of research-grade use and the institutional data from the TRIUMPH program.
The studied dose escalation schedule: 2 mg weekly starting dose, titrated in 4-week steps to target dose. Steps at 2, 4, 6 mg before reaching 9 mg or 12 mg. This slow titration is likely responsible for the relatively manageable GI tolerability profile versus the aggressive titration schedules sometimes used in community protocols. Seven additional Phase 3 readouts from the TRIUMPH program are expected in 2026. FDA approval is not expected before late 2027 at the earliest.
On September 19, 2025, the FDA granted accelerated approval to FORZINITY (elamipretide HCl) for the treatment of Barth syndrome. This is the first FDA approval of any mitochondrially targeted peptide therapy. It is a genuine milestone in the basic science of mitochondrial targeting. It is also a narrow approval for a disease affecting approximately 150 people in the United States. Those two facts need to be held together.
What elamipretide is
Elamipretide (also known as SS-31, MTP-131, and Bendavia) is a synthetic tetrapeptide developed by Dr. Hazel Szeto at Cornell University in the early 2000s. The compound's design is built around a specific structural insight: alternating aromatic and basic amino acid residues create high affinity for cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane.
Cardiolipin is not a passive structural component. It plays an active role in organizing the protein complexes of the electron transport chain, stabilizing the cristae architecture of the inner membrane, and facilitating efficient ATP production. When cardiolipin is damaged or deficient, mitochondrial function deteriorates. Energy output drops, reactive oxygen species accumulate, and cells dependent on high ATP throughput (cardiac muscle, skeletal muscle, neurons) show disproportionate dysfunction. Elamipretide binds cardiolipin and appears to stabilize the inner membrane, improving cristae organization and reducing oxidative damage.
Barth syndrome: why this was the right first indication
Barth syndrome is caused by mutations in the TAFAZZIN gene, which encodes an enzyme required for normal cardiolipin synthesis. The result is abnormal cardiolipin composition throughout the body, with the most severe consequences in cardiac and skeletal muscle. The disease presents in infancy and causes cardiomyopathy, skeletal muscle weakness, recurrent infections, and shortened lifespan. Until FORZINITY's approval, there was no disease-modifying treatment.
The mechanistic logic is unusually direct. The drug targets cardiolipin. Barth syndrome is a cardiolipin disorder. The TAZPOWER clinical trial showed significant improvements in patient-reported fatigue outcomes and functional assessments in this population. This is a clean mechanism-indication match of the type that accelerated approval programs are designed for.
What the MMPOWER-3 failure tells you
In 2023, the MMPOWER-3 randomized clinical trial evaluated elamipretide in primary mitochondrial myopathy, a broader category of mitochondrial disease. MMPOWER-3 failed its primary endpoint of 6-minute walk distance improvement. Patient-reported fatigue outcomes were positive, mirroring the Barth pattern. But the primary objective measure did not move. This failure matters because it demonstrates that elamipretide's mechanism does not automatically translate to clinical benefit across all mitochondrial disease indications. The compound is not a general-purpose mitochondrial repair agent. The Barth approval reflects a specific mechanism-disease match, not broad validation of mitochondrial-targeted therapy.
What this means for the research and biohacking community
Elamipretide is now an FDA-approved drug. That means it can be prescribed off-label by licensed physicians. It does not mean it is available through compounding pharmacies (it is not on the 503A or 503B eligible lists). It does not mean it has been validated for aging, exercise performance, or the longevity applications for which research-grade SS-31 is most commonly discussed.
A 2020 study in Aging Cell demonstrated improved mitochondrial respiration and reduced oxidative stress markers in older adults with skeletal muscle mitochondrial dysfunction after SS-31 administration. This is some of the most direct evidence of mitochondrial benefit available for any compound in the peptide research space. But this study was small, and the aging indication is a long way from the regulatory pathway that produced the Barth approval. The right framing: the Barth approval validates the cardiolipin targeting mechanism in a human population defined by cardiolipin dysfunction. That is scientifically significant. It does not validate the compound for general use.
In late February 2026, HHS Secretary Robert F. Kennedy Jr. publicly announced his intention to move approximately 14 of 19 peptides currently restricted under the FDA's Category 2 bulk drug substances list back to Category 1. If implemented, this would restore the ability of licensed 503A compounding pharmacies to legally prepare these compounds under a physician's prescription.
This is the most consequential proposed change to the peptide compounding regulatory landscape since the FDA moved those 19 compounds to Category 2 in late 2023. It has received significant coverage. Most of that coverage has overstated what has actually happened.
What Category 2 means
The FDA maintains lists of bulk drug substances that may be used in compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Category 1 substances are under evaluation and may be compounded by licensed 503A pharmacies with a valid patient-specific prescription. Category 2 substances have been identified by the FDA as presenting potential significant safety risks, which effectively prohibits compounding pharmacies from using them to prepare patient medications. Category 2 designation does not make possession of these substances illegal. The gray market for research chemicals is a separate regulatory question.
What has actually changed as of April 2026
Nothing formally. Kennedy's announcement was a statement of intent, not a regulatory action. No final rulemaking has been published in the Federal Register. No compounds have been moved from Category 2 to Category 1 through the required regulatory process. Compounding pharmacies that begin preparing Category 2 compounds based on the announcement alone are operating outside current legal parameters. The FDA has not issued enforcement discretion guidance.
This is not a criticism of the intent behind the announcement. The 2023 Category 2 designations were criticized by many clinicians and compounding pharmacy groups as scientifically unsupported, citing that the safety signals used to justify them were theoretical rather than based on documented patient harm. The proposed reclassification addresses those criticisms. But the process has to be completed before the legal framework changes.
Which compounds are expected to return to Category 1
Based on public statements and regulatory analyst assessments, the 14 compounds expected to return include BPC-157, Thymosin Beta-4 (TB-500), Thymosin Alpha-1, Ipamorelin, CJC-1295, GHK-Cu, Selank, Semax, KPV, MOTS-c, and AOD-9604, among others. These are the compounds for which the safety concerns cited in the 2023 designations were most disputed.
Which compounds are expected to stay restricted
Approximately 5 compounds are expected to remain on Category 2 based on more concrete safety concerns or near-total absence of human data. Melanotan II remains restricted due to cardiovascular and dermatological safety signals. GHRP-2 and GHRP-6 face scrutiny over cortisol and prolactin elevation effects. LL-37 has extremely limited human safety characterization. PEG-MGF has minimal clinical evidence and was never widely compounded. CJC-1295 appears in some assessments as likely Category 1 and in others as uncertain, and warrants independent monitoring as formal rulemaking progresses.
A separate but related development
On March 27, 2026, multiple outlets reported that dietary supplement manufacturers have begun lobbying the FDA to classify certain peptides as dietary supplement ingredients under the Dietary Supplement Health and Education Act. This is a completely different regulatory pathway from the Category 2 reclassification and the two should not be conflated. DSHEA classification would allow over-the-counter sale without a prescription. Category 1 classification through the compounding framework requires a prescription and physician oversight. These are different regulatory tracks with different implications for access, quality control, and legal standing.
What to watch
The Federal Register is the authoritative source for any formal reclassification. Until a final rule or interim final rule appears there, the legal status of Category 2 compounds for compounding purposes is unchanged. The Peptide Signal will update profiles for all affected compounds when formal rulemaking is published.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use